Skip to main content
. Author manuscript; available in PMC: 2020 Aug 1.
Published in final edited form as: Pharmacogenet Genomics. 2019 Aug;29(6):123–131. doi: 10.1097/FPC.0000000000000375

Figure 2. Cumulative incidence of high-grade neutropenia and competing events.

Figure 2.

The graph on the right shows the stratification by arm (gemcitabine plus placebo and gemcitabine plus bevacizumab). The vertical line represents the cut-off for the definition of early neutropenia (5 weeks).